Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed squamous, adenocarcinoma, or adenosquamous carcinoma of the cervix
• * Stage IIB-IVA OR
• * Stage IB-IIA with pelvic node metastases and/or tumor size at least 5 cm
• No small cell, carcinoid, glassy cell, clear cell, or adenoid cystic disease
• No metastatic disease outside of pelvis
• No para-aortic disease
• PATIENT CHARACTERISTICS:
• Age:
• 18 to 85
• Performance status:
• Zubrod 0-2
• Life expectancy:
• At least 6 months
• Hematopoietic:
• WBC at least 3,000/mm\^3
• Absolute granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• AST or ALT no greater than 2.5 times upper limit of normal (ULN)
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 50 mL/min
• Calcium no greater than 1.3 times ULN
• Cardiovascular:
• No severe heart disease
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• HIV negative
• No prior allergy to sulfonamides or non-steroidal anti-inflammatory drugs (NSAIDs)
• No prior hypersensitivity to celecoxib or any component of its formulation
• No medical or psychiatric illness that would preclude study
• No active gastrointestinal (GI) ulcer, GI bleeding, or inflammatory bowel disease
• No other prior malignancy within the past 5 years except cutaneous basal cell skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No recent prior celecoxib or other cyclo-oxygenase-2 inhibitor
• Chemotherapy:
• No prior systemic chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• No prior radiotherapy to pelvis except transvaginal radiotherapy to control bleeding
• Surgery:
• No prior surgery for cervical cancer except biopsy
• Other:
• No concurrent phenytoin or lithium
• No other concurrent NSAIDs